Phase Ib Clinical Study to Evaluate Safety, Tolerance Pharmacokinetics and Efficacy of SY-007 After Intravenous Injection in Acute Ischemic Stroke Subjects
Latest Information Update: 29 Jun 2022
At a glance
- Drugs K 13 (Primary)
- Indications Stroke
- Focus Adverse reactions
- Sponsors Suzhou Yabao Pharmaceutical
- 20 Jun 2022 Planned End Date changed from 25 Dec 2022 to 25 Dec 2023.
- 20 Jun 2022 Planned primary completion date changed from 25 Dec 2022 to 25 Dec 2023.
- 20 Jun 2022 Planned initiation date changed from 1 Jul 2021 to 1 Jul 2023.